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Opportunities for Computational Techniques for Multi-Omics
Integrated Personalized Medicine
Yuan Zhang, Yue Cheng, Kebin Jia , and Aidong Zhang
Abstract: Personalized medicine is defined as “a model of healthcare that is predictive, personalized, preventive,
and participator” and has very broad content. With the rapid development of high-throughput technologies, an
explosive accumulation of biological information is collected from multiple layers of biological processes, including
genomics, transcriptomics, proteomics, metabonomics, and interactomics (omics). Implementing integrative
analysis of these multiple omics data is the best way of deriving systematical and comprehensive views of living
organisms, achieving better understanding of disease mechanisms, and finding operable personalized health
treatments. With the help of computational methods, research in the field of biology and biomedicine has gained
tremendous benefits over the past few decades. In the new era of personalized medicine, we will rely more on the
assistance of computational analysis. In this paper, we briefly review the generation of multiple omics and their
basic characteristics. And then the challenges and opportunities for computational analysis are discussed and
some state-of-art analysis methods that were recently proposed by peers for integrative analysis of multiple omics
data are reviewed. We foresee that further integrated omics data platform and computational tools would help to
translate the biological knowledge to clinical usage and accelerate development of personalized medicine.
Key words: personalized medicine; translational bioinformatics; multi-omics integration

1

Introduction

Personalized medicine, as one of the most
important biomedicine developments, has arrived
together with the emergence of Translational
BioInformatics (TBI) which builds a bridge between
clinical practice and fundamental findings of
biomedicine[1] . Personalized medicine has a broad
and inclusive definition, “a model of healthcare that is
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predictive, personalized, preventive, and participator”,
or “P4 Medicine”[2, 3] . Personalized medicine optimizes
patient care and improves prescription of treatments
with higher likelihood of success by utilizing the
patient’s own genetic information and personal
clinical data[4] . The aim of personalized medicine
is to better tailor cost-effective strategies using
specific techniques based on individual biological
knowledge. It is becoming a hot topic during last
five years as shown in Fig. 1, for example, which
illustrates the number of papers that are involved in
the term of “personalized medicine” and indexed in
PubMed. Along with increasing attention that the topic
receives, the challenges of translating omics knowledge
to real clinical practices have emerged and the assistant
of computational methods is in great need.
The genomics era has yielded great advances
in deciphering some human diseases. However,
the immense complexity of biological mechanistic
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Fig. 1

Number of results found in PubMed for the term “personalized medicine”.

continues to challenge researchers’ capacity of finding
valuable answers for complicate diseases. Researchers
began to recognize the erroneous assumption that any
given human disease can be distilled down to a single
molecular determinant and a single “magic bullet”
can be identified as the therapeutic target. Although
biologists did find some successful treatments based
on this assumption during the past few decades, this
assumption has been facing increasingly limitations as
witnessed by the lack of growth of new drugs approved
for human use, remaining effectively constant at 20
to 25 new drugs per year on average for the past 20
years[5, 6] .
Moreover, the genetic factors are not the only
reason for bringing on an attack of even a simple and
classical Mendelian disorder. People carrying the same
mutation are not necessarily to suffer from the same
prophetic disease. For example, we have learned that
retinoblastoma is caused by mutations in the Rb gene,
but not all people who carry this mutation will suffer
from retinoblastoma. Even two sisters in the family
with the same mutation inherited from their parents can
develop different phenotypes and have different effects
of disease. The reason underlying here is still not clear,
but commonly it is believed that the whole genome and
the environmental risk factors should be included into
the research. In this regard, there are numerous other
inherited diseases in which the same mutation is not
expressed in all the individuals who carry it. Disease
expression is influenced by disease-modifying genes,
post-translational modification of the proteome, and
environmental factors[7] and this is called penetrance by
geneticists.
Thus, it is time to treat human diseases from a
systematical view. With the development of high-

throughput biological technology, multiple omic
data are captured by biologists, including genomics,
transcriptomics, proteomics, metabolomics, and
interactomics. These data provide a potential way of
conducting comparative analysis from different aspects,
performing systematical research based on correlations
of heterogeneous biological molecules in network
models and seeking more insightful meaning of
macromolecules in the context of dynamic progresses
which can be modeled out of multiple omic data.
Although omic data are used in both industry
and academia in the fields of bioinformatics and
translational research, these data are extracted
from exclusive experiments which show hardly
any correlation among these heterogeneous biological
molecules within the system of an organism. Hence,
one of the challenges is to match the heterogeneous data
and capture the correlations between them. The second
challenge is to model a comprehensive representation
of multiple omics of individuals using some more
intelligent approaches like network modeling which
naturally illustrate the relationships of different objects
inside a cell. The challenge lies in extracting useful
information out of these network models, either static
networks or dynamic ones, and identifying the clinical
meanings of these critical findings that can lead the
researchers to find more practicable health care or
biomedicines. The third but not the least important is to
handle the big data analysis problem.
This paper will introduce multiple omics that are
available for us to dig into and discuss specific
computational barriers and current methods of
implementing the personalized medicine research
with these heterogeneous data. And then some
representational applications in this area are introduced

Yuan Zhang et al.: Opportunities for Computational Techniques for Multi-Omics Integrated Personalized Medicine

from which we see the opportunities provided in this
interdiscipline of molecular biology, clinical biology,
and computational science.

2

Materials and Traditional Analysis in
Biomedicine Research

For computational study, the following Genomics,
Transceiptomics, Proteomics, Metabonomics, and
Interactomics (omics) data can be used[8] .
2.1

Genomics

Raw genomic data is basically referred to the sequence
reads from a specific sequencing technique. The
processed genomic data also include the mappings
of the sequence reads to a reference genome, the
variations detected against the reference genome, and
other summarized categories based on the degree of
computational modification and integration applied to
the raw data[9] . Genetic research is to link each genotype
to the specific phenotype to finally extract the reasons of
diseases, design accurate genetic medicines which point
to the specific genetic disorder, and implement better
diagnosis and treatment at the end[10] .
During the past several decades, continuous
improvements in genomic technology, including
Next-Generation Sequencing (NGS)[11, 12] , have led
to a series of breakthroughs in the field of genetic
biomedicine, especially to the individual genetic
research[13] . NGS, with its unprecedented throughput,
scalability, and speed, has greatly facilitated the study
of individual genome. NGS has greater coverage of
the genome or transcriptome and is more accurate in
detection of rare variants, haplotypes, allele usage,
insertions/deletions, splice variants, alternative start/
stop sites, and RNA editing[14] . With the invent of
NGS, the cost of sequencing a whole genome has been
greatly pulled down and will reach 1000 USD in the
near future under the cooperative effort of researches
and industries all over the world[15] . The reduced price
makes it possible for clinical use with personalized
medicine concerned. It is foreseeable that NGS will
be a great promoter for the technology of personalized
medicine.
2.2

Transcriptomics

The genome-wide gene expression data is another
data used to identify those genes which demonstrate
significant changes under the impact of certain
experimental conditions, for example, the presence
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of cancerous tumors[16] . The advent of microarray
technology has made it possible to monitor
the expression levels of thousands of genes
in parallel and the experiment explores those
genes which are differentially expressed in one
set of samples relative to another, establishing
potentially meaningful correlations between genes
and specific conditions. Moreover, filtering out
the non-differentially expressed genes can reduce
the dimensionality of the data set and facilitate
further analysis. The representative analysis of
gene expression data can be divided into several
categories according to different experimental
objectives: (1) comparing gene expression profiles
in different tissues[17, 18] ; (2) analyzing gene expression
patterns in model systems[19] , for example, when
we do research about the cell cycle process in yeast
Saccharomyces cerevisiae[20] ; (3) extracting differential
gene expression patterns in disease or pathogens[21] ;
and (4) studying gene expression in response to drug
treatments[22] . Genome-wide gene expression analysis
(transcriptomics) can therefore deliver a comprehensive
view on all genes active at a given time in a given
sample. Consequently, transcriptomics is suitable for
the first “round of discovery” in regulatory networks
and serves to put proteomic and metabolomic markers
into a larger biological perspective.
2.3

Proteomics

The genomic data and transcriptomic data are
immensely powerful, yet it is incomplete to deliver
personalized medicine if we are not able to measure
the relevant molecular phenotype of individuals in
real time and over time[23] . Proteins offer the most
potential for personalized medicine design as they show
the real state of individual health or disease. Since
diseases will affect the protein levels inside human
body, and also the drug that is used to treat the
disease will change the protein expression by different
levels, proteomic data are used to analyze the different
effects of drugs to individuals[24] . Protein expression
can be derived from blood, tissue or other biological
samples using techniques like 2D gels, immunoassays
or the latest Mass Spectrometry (MS)[25] . Kim et al. [26]
proposed a framework of predicting individual drug
sensitivity in cancer using proteomic data. In their work,
the proteomic information of cancer was collected
by Reverse-Phase Protein Array (RPPA) technology
and the drug sensitivity, i.e., drug resistance or
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intolerance, served as training label in their Augmented
Naive Bayesian Classifier (ANBC). Once the ANBC
was trained, it could be used to predict the drug
sensitivity for another individual. As one of the most
instant measurement of health state, protein levels are
attracting great attention for drug development and
disease diagnose.
2.4

Metabonomics

Metabolic phenotype is the downstream of genetics
and environmental effects which can be used
to measure and analyze the disease or drug
outcomes[27] . Metabonomics profile can be collected by
Nuclear Magnetic Resonance (NMR) spectroscopy[28]
and mass spectrometry.
The clinicians have been using metabolimics as
biomarkers to diagnose and predict diseases[29] . It
is also the final aim of metabolimics to identify
effective biomarkers. For example, the patients
with colorectal cancer[30] and normal samples were
studied comparatively by the NMR-based metabolic
profiling. They observed upregulated lipid-based
resonances in pretreated patients that showed poisoned
phenomenon after dosing. Their work shows that it is
possible to predict toxicity and design best treatments
for a patient by studying the predose patterns of
metabolics. Several studies have also investigated the
drug efficacy of cancers like the different responses of
MCF7 breast cancer cells to treatment with docetaxel,
which is used in the treatment of advanced or metastatic
breast cancer[31] . Metabolic data have also been used
to identify the prognostic biomarkers and stratify
disease subtypes like rheumatoid arthritis, diabetes, and
Alzheimer’s disease.
2.5

Interactomics

Molecules inside cells don’t perform their functions
alone, but tend to interact with others for proper
biological activities[32] . Varying molecular interactions
exist among different biomedical families and compose
varying interactiomic. Interactions between proteins
are described by Protein-Protein Interaction (PPI)
data which have been serving as the most important
knowledge of studying proteins functions besides
protein structure information. Also, protein-DNA
interactions are studied to get the regulatory
relationships between proteins and genes, and the
nodes inside the network include transcription factors,
chromatin regulatory proteins, and the targeted

genes. The metabolic molecules can also be illustrated
in a network where the chemical compounds are
converted into each other by enzymes which have to
bind their substrates physically. In these networks,
all the related biological molecules are represented
as vertices and the interactions as edges. Network,
or graph, is a very systematical way of illustrating
the interactomic information. Using graph theory and
network mining technologies we are able to do more
systematical analysis with these interactomic data.
The public available datasets for the above omics are
shown in Table 1.

3

Computational Integrative Analysis of
Multiple Omics in Personalized Medicine

The advanced biological measurements of multiple
omics provide tons of data about diseases for
the medical paradigm of “measure, diagnose, and
treat”, yet none of the various human omics are
complete to make this challenge on its own because
of the noise, incompleteness, and other tentative
limitations. It is quite natural to analyze heterogeneous
data integratively using either statistical or more
intelligent computational methods and conquer the
challenges that hinder us from “seeing” deeper
biological mechanics of diseases.
In the workflow of data-driven personalized medicine
research, the fundamental issue is to estimate the
biological features of individual multi-omics data which
is also the base of integration analysis of multiple
omics, multiple platform, and multiple organisms. The
second issue is to create data integration models
according to different applications including identifying
predictive and prognostic biomarkers for relevant
treatments[33] , predicting diseases, and recognizing
disease states[34] .
There are generally two directions of integrative
analysis: On one side, we need to design efficient
methods to interpret each of these data in their own
right; and on the other side, careful integrative statistical
or more systematical methods of multi-omics analysis
should be designed considering the difficulties of
ID conversion, object mapping, heterogeneous data
handling and mining, and so on. Moreover, the
correlations and causal relationships between different
omics layers should also be addressed to get more
insightful and systematical understanding of biological
progress[35, 36] .

Yuan Zhang et al.: Opportunities for Computational Techniques for Multi-Omics Integrated Personalized Medicine
Table 1a
Data types

Online resource
The Cancer Genome
Atlas (TCGA)
1000 Genome

Genomics

Transcriptomics

Gene
Expression
Omnibus (GEO)
Stanford
Microarray
Database (SMD)
World-2DPAGE

Proteomics

The
PRoteomics
IDEntifications
(PRIDE) database

Metabolomics

The
Human
Metabolome Database
(HMDB)

Data types
Protein-DNA
interactions

Protein-protein
interactions

3.1

Online resource
Biomolecular Network
Database (BIND)
Encyclopedia of DNA
Elements (ENCODE)
Database of Interacting
Protein (DIP)
Biological
General
Repository
for
Interaction
Datasets
(BioGRID) (Till April
12, 2014)
InAct (Till April 12,
2014)

Omics database (Components)

Description
Contains clinical information, genomic
characterization data, and high level sequence
analysis of the tumor genomes.
The first project to sequence the genomes of
a large number of people, and to provide
a comprehensive resource on human genetic
variation, including 2577 samples from all over
the world.
Microarray and SAGE-based genome-wide
expression profiles.
Microarray-based genome-wide expression
data.
A public standards-compliant repository for
gel-based Proteomics data linked to protein
identification published in the literature.
A centralized, standards compliant, public
data repository for proteomics data of 1670
projects and 33 230 assays, including protein
and peptide identifications, post-translational
modifications and supporting spectral evidence.
A freely available electronic database
containing detailed information about small
molecule metabolites found in the human body.

Table 1b
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URL
http://www.broadinstitute.org/
software/igv/tcga
http://www.1000genomes.org/data

http://www.ncbi.nlm.nih.gov/geo
http://genomewww.stanford.edu/microarray
http://us.expasy.org/ch2d/2dindex.html
http://www.ebi.ac.uk/pride
/archive/

www.hmdb.ca/

Omics database (Interactions)

Description
Published protein-DNA interactions.

URL
http://www.bind.ca/Action/

Database of functional elements in human
DNA.
6678 articles for 76 844 protein interactions of
26 453 proteins.
42 396 publications for 737 271 raw protein
and genetic interactions from major model
organism species.

http://genome.ucsc.edu/ENCODE
/index.html
http://dip.doembi.ucla.edu/dip/Stat.cgi
http://thebiogrid.org/

12 659 publications for 445 718 protein,
compound, nucleic acids and genetic
interactions of 82 232 interactors from 32 878
experiments.

http://www.ebi.ac.uk/intact/

Single-sample estimation

Many biotechnology high-throughput platforms for
gene expression profiling, sequencing, and protein
expression profiling are invented during the past few
years. These platforms are designed to technologyspecific biases and produce raw data of distinct
distributions. To get an integrative analysis of multiple
platform data, the fundamental challenge is to solve the
normalization problem[37] .

Bengtsson et al. [38] proposed a single-sample multi
source normalization method that brought different
copy numbers from multiple platforms to the same
mean levels. This method assumed a non-linear
measurement function among the observed copy
numbers. Using a kernel-based estimation procedure,
the complete copy numbers at a common set of loci
are obtained for the further normalization function
estimation. And to model the non-linear normalization
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function, a principal curves[39] based on PCA analysis
was adopted. Single-sample normalization methods for
microarray, qPCR, and RNA-Seq experiments[37, 40, 41]
are also developed with great potential of assisting the
personalized analysis. Although it is still unproved of
the validity of comparing platforms, labs, or algorithms
based on these normalizing estimation, this work is an
effective attempt.
The single-sample estimation presents another major
problem of “large p, small n”. In the framework
of personalized medicine prediction, techniques of
dimensionality reduction, sparsity estimation, rulebased models, and expert systems can best serve the
purpose of translational analysis. Some researchers
use knowledge-driven strategy and adopt existing
datasets from population studies to compensate the
insufficient sample information. For example, Liu et
al.[42] discussed the possibility of identifying critical
transitions as the biomarkers of complex diseases based
on a single sample by exploiting existing disease
samples.
3.2

Jointly comparative analysis of multiple omics

Tremendous studies have shown the outstanding power
of the jointly comparative analysis of multiple omics
data than separate analysis[35, 43-45] .
Liu et al.[35] proposed a comparative analysis
framework of jointly analyzing multiple omics data
including the miRNA, gene, and protein expression in
which these data were normalized and integrated into
a joint matrix and decomposed with factor analysis
and linear discriminate analysis methods to extract the
useful factors inside the multiple types of information
for cancer subtype identification. They reported great
improvement of identifying mutations drivers in cancers
than the separate analysis with each omics layer or
other traditional joint analysis methods like SAM. By
modeling multiple omics in microbes, Cotton and
Reed[46] proposed a multi-omics based optimization
method for estimating the kinetic rate parameters of
constraining metabolic fluxes in Escherichia coli. Using
this integrative but simplified kinetic model, they
showed us a more general way of predicting the
intracellular fluxes and biomass yield and identifying
potential metabolic limitations through the integrated
analysis of multi-omics datasets.
In the research of recombinant protein producing,
Dietmair et al.[44] implemented a jointly comparison
of the combination of transcriptomics, metabolomics,

and fluxomics of a recombination protein producing
Hek293 cell line and its parental cell line to reveal a
surprising observation that the consumption of glucose
of the producer cell line is less than the non-producer
cell line despite the additional burden of recombinant
protein production, and the same happened to the
glutamine consumption which was also lower than
the non-producer cell line. With the joint comparison
of genomics, they also found that the majority of
genes involved in oxidative phosphorylation and broad
cellular functions were down-regulated in producer
cultures. With these findings, the researchers presented
the speculation that there must be a large scale of
cellular network adaption for the recombinant protein
production which made bountiful resources available
for this specific progress possible. With the indication
of endoplasmic reticulum stress, they suspected that
the possible hurdle of recombinant protein production
might lie at the point of protein folding and assembly.
Based on these researches, we can say that the
jointly comparative analysis of multiple layers of
omics provides more insightful knowledge about the
diseases or biological progresses and gives us a more
comprehensive view of the biological system which,
with great potential, will help us to develop more
accurate and lower-cost treatments and health care in
clinical activities.
3.3

Network-based analysis

Networks are the natural representations of the
biological systems inside a cell by illustrating the
interaction relationships among the molecules. Network
analysis or graph analysis is a systematical way of
studying the mechanics of biological progresses within
human body[47] . As introduced in Section 2, the
interactomics data have been used in the personalized
medicine research. However, the current interatomic
databases are far from complete for fully modeling
the complex biological progresses. For example, there
are no genes or other molecules other than proteins
that are included in PPI networks. And for the other
thing, the current biological networks are generally
accumulated from all kinds of experiments, but without
temporal information therefore with these networks,
it is impossible to describe the dynamic changes of
biological processes. In this section, we introduce the
challenges and also the opportunities for computational
technologies in the content of network modeling of
multiple omics analysis.
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3.3.1

Heterogeneous component networks

As in the multiple omics data, there are heterogeneous
components. One way of representing these omic
information is to find the correlations between different
networks of single sort of components, and the other is
to integrate these components into one comprehensive
network which shows the complex relationships among
them. We observe tremendous challenges from both
perspectives.
For the first line of research, there are many
researchers who adopted compensational information
to correct their vital ones, like the works that
use gene expression to confirm the interactions
between proteins[48-50] . The co-expression correlations
are computed and added into the networks as the
edge weights. Besides, some works have implied that
similarly to the genome conservation, the protein
interactions have conserved along the evolution to a
great extent[51-53] . Hence there were some researchers
used interactomic data from other organisms to verify
the targeted PPI data[54] . As shown in Fig. 2, Du et al.[54]
adopted three auxiliary interaction networks of other
species — C.elegans, H.plylori, and S.cerecisiae to denoise the target interaction network. Using the links
of auxiliary networks and the similarity of the nodes
between the auxiliary networks and target networks,
link propagation techniques were performed to predict
the links in the target network. The effectiveness of the
cross-organism analysis method was verified on known
PPI datasets by blocking partial links for prediction.
In Gat-Viks’ work[55] , they proposed a method of
constructing a regulatory network out of multiple
biological
networks
including
heterogeneous
components (mRNA, proteins, and metabolites). Using
lysine biosynthesis pathway as a research case,

they claimed that the method provided a prediction
methodology in the presence of cycles and a polynomial
time, constant factor approximation for learning the
regulation of a single entity. In this line of work,
another basic process is to match the entities in different
omics[56] and some public tools are available for this
problem, including the DAVID[57] , MatchMiner[58] ,
and other ID mapping tools from public biological
databases[59] .
For the second line of research, which is more
complicated, some works attempted to construct a
comprehensive network for heterogeneous components.
Yeang and Vingron[60] studied the gene regulation and
metabolic reactions in Escherichia coli by adding links
specifying the feedback control from the substrates of
metabolic reactions to enzyme gene expressions. A
joint network was constructed in their work which
adopted both genes and metablites. They inferred the
feedback links between metabolites and transcription
factors by fitting the perturbation data in a probabilistic
graphical model on one side, and on the other
side they directly encoded general hypotheses about
metabolic enzyme regulations with enzyme expression
data to get the feedback control from metabolites and
corresponding genes. The perturbation data included
5 sources covering from gene expression data to
metabolics[60] . This work provides a way of building
a bridge between the gene regulation and metabolic
reaction systems.
There were some other researchers proposing to
simultaneously process multiple heterogeneous
networks and identify the interested patterns of
multi-omics data in a unified fashion. In Mosca
and Milanesis’ work[61] , based on PPI interactions,
different views of interactome are constructed by
adding different weights to the PPI network and a
multi-objective optimization model was developed
to identify networks that are optimal according to
several scores which make the optimization results of
biological meaning, for example, they identified the
differentially expressed networks of PPIs that regulated
the basal cancer markers which are believed to be
related to breast cancer.
3.3.2

Fig. 2 The structure of mapping the external labeled
information to the target network[54] .
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Dynamic networks

Biological systems are inherently dynamic in
nature. However, most of the public biological
networks, like PPI datasets, are simply the aggregation
of all the possible interactions occurring in all
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examined conditions[62] , and the temporal changes of
these networks are ignored. In PPI networks, proteins
have active forms and perform their functions at
specific time courses and environments. Similarly
metabolites can be present or absent to certain
biological progress. Dynamic biological networks
illustrate the real state of molecules inside human body
and are the best sources for personalized medicine
research. Analysis of dynamic networks falls into
several categories similar to static network analysis,
including interaction detection also known as dynamic
PPI network construction, complex identification, and
critical node detection.
Extracting dynamic PPI networks from the
known PPI datasets is the basic task for dynamic
analysis. Basically, there are two main directions to
construct dynamic PPI networks. One is based on the
differential co-expression correlations. Researchers[63]
have shown that the highly positive co-expressed
proteins tend to form most static modules. At the center
of these modules there are some hubs with high degree
namely “party” hubs, which tend to appear at all of
the time points. Meanwhile, there are some lower
positive co-expressed proteins which are believed
to interact at some particular time points. Among
these proteins the hubs are called “date” hubs and
are believed to be the cause of dynamic interactions
and also may induce aberrant pathways and molecular
disorders. Taylor et al.[64] observed a multi-modal
distribution of gene expression correlation coefficients
using a literature-curated source. The other way to
construct dynamic PPI networks is based on expression
variance[65] . They determine the peak time points of
expression for each protein. If a protein is at its peak
point, it is said to be in its active form and can interact
with its active neighbors. Based on this assumption,
scored gene expression activity is computed using a
single threshold[66] or a systematical threshold[67] in
literature. In addition, some researchers argue that the
gene expression data contain far more noise that will
induce unauthentic factors. For example, the genes
are sent into a filter that defines a criterion for genes
of being dynamic or stable in Xiao et al.’s paper[68] ,
and the stable ones are left out of the subsequent
construction of dynamic networks.
Complex detection in dynamic networks is more
challenging than the problem in static networks
because both the number of proteins and complexes
are changing during the biological progress. A

heuristic dynamic module detection method was
presented by Jin et al.[69] , which performs a DepthFirst Search (DFS) style enumeration in temporal
networks to find the dynamic modules, the connected
subgraphs, in both the temporal network and the
corresponding second order network. Some other
researchers proposed effective algorithms to overtake
the challenge of changing number of proteins and
complexes across biological processes. One of these
works is based on the Bayesian graphical model which
incorporates two priors to approximate the changing
number of complexes at different times[70] . These
researchers showed that dynamic network complexes or
modules are more biologically meaningful than static
modules by evaluating the functional homogeneity
of dynamic modules with Gene Ontology (GO)
annotations[69, 70] . Another characteristic for the
dynamic modules is that a majority of them are very
sparse which is very challenging to detect for the
topology-based analysis of static network. Moreover,
there is an assumption about the smoothness among
adjacency networks that is usually utilized in functional
module detection for dynamic network[71] . Dynamic
network analysis can facilitate the identification of
likely important insights that are otherwise easily
overlooked.
The other application of dynamic network analysis
in personalized medicine research is to identify critical
biomarkers using the dynamic properties. Dynamic
network biomarkers show higher or lower expression
compared with the normal cases, meantime they
have time dependent stronger or weaker interactions
with their neighbors. It has considered as one of
powerful ways to detect the bifurcation of gene
or protein interactions, indicating the early change
of biomarkers and predicting the occurrence of
diseases[72] . Dynamic network biomarkers show
the advantage of demonstrating pathophysiological
changes at different stages and periods. The disease
specificity of dynamic network biomarkers should be
validated by the integration with clinical informatics
which translates clinical descriptive information on
complaints, sign, symptoms, biochemical analyses,
imaging, and therapies into the digital data[73] . One of
the most challenges is to detect the abnormal changes of
network structures. It is assumed that biomarkers are a
minority group in networks and this assumption is true
in most cases and treats the biomarker detection
of dynamic networks as an anomaly detection
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problem[74] . Data mining technologies including
graphic probabilistic model, clustering, and network
comparison, are basic algorithms that can be utilized in
the dynamic network mining problem.
3.4

Big data analysis

In the past decade, biologists experienced an era of
data “Tsunami” in which the amount of biological data
accumulated at a rate that exceeds Moore’s Law and
the acceleration continues at the scale and at multiple
levels, i.e., the multiple omics[75] . With the 1000
USD Genome approaching, it will be quite convenient
to get the genome of individual patients[76] . Just a
single human genome takes 140 GB in size. Hence,
the production of petabytes of omics data is of great
challenge to the existing computational technology in
the respects of data storage and maintenance, transfer
and quality control, especially data integration and
data mining analysis[77] . New frameworks and powerful
computational tools must be invented to tackling the
data mountains.
Newly developed open source software framework
for parallel computation, called Hadoop, is one
of the powerful platforms to deal with petabytes
data[78, 79] . This platform provides a foundation for
scaling to petabyte scale data warehouses on Linux
clusters, providing fault-tolerant parallelized analysis
on such data using a programming style named
MapReduce. Except for the criteria about system
components, data location, Fault-tolerant, sharednothing architecture, and the reliability guarantee, the
MapReduce paradigm is core technology of realizing

Pre‐loaded local
input data

parallel computation in Hadoop. There are two steps:
Map and Reduce, where each step is done in parallel
and operating on sets of key-value pairs. These two
steps are separated by the data transfer between nodes
in the cluster[80] . In the MapReduce paradigm which is
shown in Fig. 3, input data are loaded to the processing
cluster in HDFS file management system. And these
files are evenly distributed across all nodes. For the
mapping phase, each node runs equivalent mapping
tasks, which means all mappers are identical and any
mapper can process any input file. At the end of Map
phase, we get a set of records of key-value pairs which
must be exchanged between machines to send all values
with the same key to a single reducer. Then in the
Reduce phase, a distinct task is performed on a single
node. The Reduce stage produces another set of keyvalue pairs, as final output.
Hadoop
supports
programming
to
each
computational task’s need, which is quite different
from MPI-based parallel programming[82] . There are
some successful implementations of bioinformatics
tools like BLAST and Gene Set Enrichment Analysis
(GSEA) in Hadoop. Although Hadoop is designed to
run on industry-standard hardware, an ideal cluster
configuration is required to get it run stably and
efficiently which also means expensive investment. An
economical way of implementing the parallel
computing is to rent commercial cloud hosting services
like Amazon Elastic Compute Cloud (EC2)[83] , Google
AppEngine[84] , and Microsoft Azure[85] . A number of
bioinformatics systems have been developed on the
top of cloud computing infrastructure. Table 2 shows

Node 1

Node 2

Node 3

Mapping process

Mapping process

Mapping process

Node 1

Node 2

Node 3

Reducing process

Reducing process

Reducing process

Intermediate data
from mappers
Values exchanged
by shuffle process
Reducing process
generates outputs

Outputs stored
locally

Fig. 3
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High-level MapReduce pipeline[81] .
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Table 2
Infrastructure
Cloudburst
Crossbow
Contrail
Myrna
Biodoop
CloudBLAST
Bionimbus
BioVLAB-MMIA

Current frameworks for big bio-data.

Description
Map next-generation short read sequencing data to a
reference genome for SNP discovery and genotyping
Whole genome resequencing analysis and SNP genotyping
from short reads
De novo assembly from short sequencing reads
Calculate differential gene expression from large RNA-seq
data sets
Three qualitatively different algorithms: BLAST, GSEA and
GRAMMAR.
A parallelized version of the NCBI BLAST2 algorithm
A cloud for managing, analyzing, and sharing large genomics
datasets
Integrated analysis of microRNA and mRNA expression data

some current frameworks for big bio-data analysis. We
see that these frameworks most focus on only one
kind of omics, except the BioVLAB-MMIA which
compares inversely correlated expression patterns
between microRNA and mRNA and is built upon the
Open Grid Computing Environments workflow suite
tools and Amazon computing cloud resources[86] . More
and more institutions are paying attention on using
Hadoop on biological data integration, for example,
the Environmental Molecular Sciences Laboratory[87] ,
a national user facility located at the U.S. Department
of Energy’s Pacific Northwest National Laboratory
(PNNL), and the U.S. Dept. of Energy[88] . This is
merely a beginning of integration analysis of big multiomics. A wide range of bioinformatics applications
maintaining good computational efficiency, scalability,
and ease of maintenance are needed in the future. Also
facilitated by the programming support characteristic,
some advanced data mining and network modeling
algorithms can be transformed to parallel fashion and
run on MapReduce clusters[89] .

4

Conclusions

Over the past few decades, computational methods have
greatly helped the analysis of biological information. In
the new post-genomic era, computational analysis will
play an even vital part in integrating multiple omics
data to realize personalized medicine technology. In this
paper, we briefly reviewed the generation of multiple
omics data and their basic characteristics. And then the
challenges and opportunities for computational analysis
are discussed and some state-of-art analysis methods
of implementing integrative analysis of multiple omics

Platform
Hadoop
EC2

Elastic MapReduce / a local
Hadoop-based cluster
Hadoop

Reference
[90]
[91]
[92]
[93]
[80]

Hadoop

[94]
[95]

EC2 and S3

[86]

data are reviewed. Under their specific applications,
the reviewed computational multi-omics integration
analysis provides insightful understanding of diseases
or drug reactions, identifies biomarkers and critical
targeted functional molecules, and classifies disease
subtypes. We foresee that further integrated omics
data platform and computational tools would help to
translate the biological knowledge to clinical usage and
accelerate development of personalized medicine. What
is more, although this paper focused on the multiple
omics data integration, clinical diagnosis, patient
screening, and other prior knowledge about patients can
be utilized in a more broader scenario of personalized
medicine.
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